Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 2/3 1Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colonic Neoplasms 7Colorectal Neoplasms 6Rectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Liver Neoplasms 2Head and Neck Neoplasms 2Hand-Foot Syndrome 2Adenomatous Polyposis Coli 2Smoking 1Pancreatic Neoplasms 1Pain, Postoperative 1Pain 1Nasopharyngeal Carcinoma 1Lymphoma, Follicular 1Lung Neoplasms 1Influenza, Human 1Drug-Related Side Effects and Adverse Reactions 1Breast Neoplasms, Male 1Agnosia 1Adenocarcinoma of Lung 1

Interventions

Sulindac 2Eflornithine 2Celecoxib 2Docosahexaenoic Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Adenomatous Polyposis Coli × Celecoxib × Clear all
NCT06545526 2024-08-09

Chemopreventive Effect of Combination of Celecoxib and Metformin in Patients With Familial Adenomatous Polyposis

Yonsei University

Phase 3 Recruiting
28 enrolled
Gastrointestinal

Adenomatous Polyposis Coli

NCT00585312 2021-02-21

CHIP

Pfizer

Phase 3 Terminated
106 enrolled 10 charts
Gastrointestinal

Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡